The TITRATION trial investigated two strategies to initiate and up-titrate sacubitril/valsartan (LCZ696) to the same target dose, over a condensed (3-week) or conservative (6-week) period, in patients with heart failure with reduced ejection fraction (HFrEF) and systolic blood pressure (SBP) of ≥100 mmHg. This post hoc analysis examined the relationship between baseline SBP at screening and achievement of the target dose of sacubitril/valsartan of 97 mg/103 mg (also termed 'LCZ696 200 mg') twice per day during the study. 
Introduction
Sacubitril/valsartan (also termed LCZ696) is an angiotensin receptor neprilysin inhibitor (ARNI) approved for the treatment of patients with symptomatic chronic heart failure with reduced ejection fraction (HFrEF). 1, 2 In the pivotal Prospective comparison of angiotensin receptor neprilysin inhibitor with angiotensin-converting enzyme inhibitor (ACEI) to Determine Impact on Global Mortality and morbidity in Heart Failure (PARADIGM-HF) trial, treatment with sacubitril/valsartan, at target doses, significantly reduced cardiovascular death, heart failure (HF) hospitalization, and all-cause mortality compared with the ACEI enalapril in patients with HFrEF.
3 -5 The TITRATION trial investigated dose escalation strategies to characterize the safety and tolerability of initiating and up-titrating sacubitril/valsartan to the same target dose over 3 or 6 weeks in patients with HFrEF. 6 In this study, the initiation or up-titration of sacubitril/valsartan were found to be well tolerated regardless of the up-titration regimen, and approximately 76% of all patients achieved and maintained the target dose of sacubitril/valsartan without dose interruption/down-titration over 12 weeks. This was seen irrespective of prior ACEI/angiotensin receptor blocker (ARB) dose [including zero dose (i.e. in 33 ACEI/ARB-naive patients)]. The target dose was also achieved in patients requiring temporary dose interruptions, and a more gradual up-titration strategy maximized attainment of the target dose in patients previously on low-dose ACEI/ARB and in ACEI/ARB-naive patients. 6 This is important in the context of recent findings from the PARADIGM-HF trial, in which any dose reduction, irrespective of treatment group, was associated with a higher subsequent risk for adverse cardiovascular outcomes. 5 Low systolic blood pressure (SBP) is associated with a relatively poor prognosis and is often considered a barrier to starting and/or up-titrating HF therapies to the target dose. 7 -9 In a recent analysis from the Systolic Heart Failure Treatment with the I f Inhibitor Ivabradine (SHIFT) trial, every 10-mmHg lower baseline SBP was associated with a 12% higher risk for all-cause mortality in patients with chronic HFrEF receiving background contemporary medical therapies.
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Because of its dual mode of action, the ARNI sacubitril/valsartan induces greater reductions in blood pressure than do ACEIs and ARBs, which may lead to concerns among physicians regarding its routine use in patients with low SBP. The objective of this post hoc analysis of the TITRATION trial was to investigate the relationship between SBP at screening and the successful initiation and up-titration of sacubitril/valsartan to target doses in patients with HFrEF.
Methods

Study design and study population
The design and results of TITRATION (NCT01922089) have been published elsewhere. 6 Briefly, hospitalized and outpatient male and female patients (aged ≥18 years) with a diagnosis of HFrEF ejection fraction (LVEF) of ≤35%, and receiving a stable dose (for at least 4 weeks) of an ACEI/ARB or being ACEI/ARB-naive (not taking an ACEI/ARB for at least 4 weeks) could be enrolled in the study. Hospitalized patients taking any tolerated dose of ACEI/ARB for any length of time or ACEI/ARB-naive patients could also be enrolled. Patients were required to have been receiving treatment with other guideline-recommended therapy for HFrEF. Patients with symptomatic hypotension and/or SBP of <100 mmHg or >180 mmHg at screening, an estimated glomerular filtration rate (eGFR) of <30 mL/min/1.73 m 2 or a known history of angioedema were excluded.
The study design included a short, open-label, run-in period (5 days) during which all enrolled patients initiated sacubitril/valsartan at a dose of 24 mg/26 mg (also termed 'LCZ696 50 mg') twice per day. This was followed by an 11-week double-blind randomization period during which the dose of sacubitril/valsartan was up-titrated to a target dose of 97 mg/103 mg (also termed 'LCZ696 200 mg') twice per day over a 3-week ('condensed') or 6-week ('conservative') period to determine whether the tolerability of initiating sacubitril/valsartan is affected by the duration of the initiation/up-titration regimen. Patients requiring dose reduction or dose interruption were switched to open-label sacubitril/valsartan, wherein the dose was up-titrated based on the investigator's judgement with the aim of achieving and maintaining the target dose of sacubitril/valsartan 97 mg/103 mg twice per day. The study design is presented in the supplementary material online, Figure S1 .
The study was conducted in accordance with the International Conference on Harmonization Guidelines for Good Clinical Practice and the Declaration of Helsinki. The protocol was approved by each site's ethics committee; all patients provided written informed consent.
Study assessments and statistical analysis
For the current analysis, all patients who entered the randomized phase were categorized in four SBP groups based upon their SBP at screening (Visit 1): 100-110 mmHg; 111-120 mmHg; 121-139 mmHg; and ≥140 mmHg. The SBP cut-offs were selected on the basis of common cut-off values used in the clinical setting to reflect patients with normal SBP and those with hypertension or low SBP. Baseline characteristics are presented for the four SBP groups as numbers and percentages for categorical variables, and as the mean ± standard deviation (SD) for continuous variables.
To study the effect of SBP at screening on the tolerability of sacubitril/valsartan, the proportion of patients, excluding non-adverse event (AE)/death-related discontinuations, who achieved and maintained the target dose of sacubitril/valsartan 97 mg/103 mg twice per day without any dose interruption or down-titration over 12 weeks (defined as 'treatment success') was estimated for each SBP group. Similarly, the proportion of patients who tolerated sacubitril/valsartan 97 mg/103 mg twice per day for at least the final 2 weeks leading to study completion, regardless of previous dose interruption or down-titration, (defined as 'tolerability success') was also estimated for each SBP group.
The incidences of prespecified AEs in the randomized population [investigator-reported hypotension (Medical Dictionary for Regulatory Activities-MedDRA preferred terms: hypotension, orthostatic hypotension, blood pressure decrease), hyperkalaemia (Med-DRA preferred terms: hyperkalaemia, blood potassium increase) and renal dysfunction (MedDRA preferred terms: blood creatinine increase, glomerular filtration rate decrease, renal failure, renal failure acute, renal failure chronic, renal impairment)], the proportion of patients with SBP of <95 mmHg and the results of pre-specified laboratory assessments [serum potassium >5.5 mmol/L and ≥6.0 mmol/L and serum creatinine >3.0 mg/dL (267 μmol/L)] are presented as numbers and percentages for each SBP group. A post hoc analysis was performed to assess the change in SBP from baseline at 12 weeks and the proportion of patients in each SBP stratum who experienced a 20% or 30% reduction in SBP from baseline according to the assigned up-titration regimen.
To quantify the effects of lower SBP at screening on incidences of these events, data were analysed using logistic regression with factors for region, SBP subgroup, high/low ACEI/ARB stratum and randomized up-titration group (condensed/conservative), to provide odds ratios with 95% confidence intervals with comparisons for each higher SBP category made with reference to the lower SBP 100-110 mmHg group. To explore how the effect of screening SBP on incidences of these events varies by up-titration regimen, P-values from interaction tests were calculated.
All P-values were two-sided. A P-value of <0.05 was considered to indicate statistical significance. However, although P-values are presented, it is important to note that the study was not powered to detect statistically significant differences between regimens. All statistical analyses were performed using SAS version 9.4 (SAS Institute, Inc., Cary, NC, USA).
Results
Baseline demographic and clinical characteristics
In the 498 randomized patients, the mean ± SD SBP was 130.8 ± 16.3 mmHg. Overall, 167 (33.5%), 168 (33.7%), 93 (18.7%) and 70 (14.1%) patients had SBP of ≥140 mmHg, 121-139 mmHg, 111-120 mmHg and 100-110 mmHg, respectively, at screening. Baseline demographics and clinical characteristics, including medical history and treatment by SBP group, are presented in Tables 1 and 2 . In general, baseline characteristics were well balanced across the SBP categories, although patients with SBP of 100-110 mmHg were more likely to have an LVEF of <30% and to have been hospitalized for HF. As SBP was not included as a factor for randomization in TITRATION, there were some minor differences in the proportions of patients receiving the different sacubitril/valsartan up-titration regimens.
Treatment success
The proportion of patients tolerating the target dose of sacubitril/valsartan without any dose interruption or down-titration over 12 weeks, defined as indicating treatment success, was highest in the two groups with SBP of >120 mmHg, in which >80% of patients achieved and maintained the target dose of sacubitril/valsartan without any dose interruption or down-titration for the full study duration (12 weeks) ( Table 3 and Figure 1) . A slightly lower proportion of patients (76.1%) with SBP in the range of 111-120 mmHg achieved this goal, as did an even lower proportion of patients (72.7%) with SBP of 100-110 mmHg. Compared with patients with SBP of 100-110 mmHg, there were no statistically significant differences in rates of treatment success in the higher SBP categories: 111-120 mmHg, P = 0. and ≥140 mmHg, P = 0.248 (Table 3 and supplementary material online, Table S1 ).
With a gradual up-titration regimen, a greater proportion of patients achieved treatment success across all the SBP groups ( Table 3 , Figure 1 and supplementary material online, Table S1 ). Specifically, 80.0% of patients with SBP of ≤120 mmHg achieved treatment success with gradual up-titration, whereas 68.9% of patients with a more rapid up-titration regimen did so. Although the number of ACEI/ARB-naive patients was too few to determine whether target dose achievement and tolerability might differ in them, these outcomes were examined according to ACEI/ARB dose at screening. Rates of treatment success were generally comparable between the low-dose/naive ACEI/ARB and high-dose ACEI/ARB groups across the SBP categories, with no interaction between SBP at screening and pre-study ACEI/ARB dose levels (supplementary material online, Figure S2 and Table S2 ).
Tolerability success
Overall, 85.2% (397/466) of patients in the total cohort treated with sacubitril/valsartan achieved tolerability success (i.e. these patients tolerated the target dose of sacubitril/valsartan for at least the final 2 weeks prior to study completion, regardless of previous dose interruption or down-titration), excluding those in whom the treatment was discontinued for reasons other than an AE or death. When evaluated by SBP category, tolerance was highest in patients with SBP in the range of 121-139 mmHg, among whom 90.6% of patients achieved the objective ( Table 3 and Figure 1 ). Among patients with SBP of 100-110 mmHg, 75.8% achieved tolerability success, as did a slightly higher proportion of patients with SBP in the range of 111-120 mmHg (78.4%).
However, in both the SBP 100-110 mmHg and SBP 111-120 mmHg patient groups, the rate of successful tolerance was higher (approximately 82.0%) in those patients receiving gradual up-titration. The great majority of patients with SBP of >120 mmHg achieved tolerability success regardless of the up-titration regimen (Table 3, Figure 1 and supplementary material online, Table S1 ). There was no interaction between SBP at screening and pre-study ACEI/ARB dose levels for the rate of tolerability success (supplementary material online, Figure S2 and Table S2 ).
Incidence of prespecified safety events in each systolic blood pressure group
Overall, as anticipated, the highest incidences of hypotension-related AEs and SBP of <95 mmHg occurred among patients in the lowest SBP category (100-110 mmHg) ( Table 4) . Incidences of renal dysfunction and hyperkalaemia were generally comparable across the SBP groups; there was no clear trend of difference between the high and low SBP groups or between hypotension AEs and incidences of renal dysfunction and hyperkalaemia. Incidences of laboratory abnormalities were broadly comparable across the SBP groups; in general, such findings were infrequent. The reasons for which patients required dose adjustments/down-titration are presented in the supplementary material online, Table S3 . Across all SBP categories, ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; SBP, systolic blood pressure; SD, standard deviation. a Blood pressure at screening (Visit 1). b Mean ± SD SBP in the overall population. Mean ± SD SBP and DBP values are presented for Visit 2 (before the start of the run-in period and after the ACEI/ARB washout). c Included in the overall low-dose ACEI/ARB stratum.
hypotension-related AEs were the most common reason for initial treatment discontinuation, and were more frequent in patients with the lowest SBP at screening.
Change in systolic blood pressure from screening to end of study
The changes in SBP at 12 weeks in patients receiving conservative and condensed sacubitril/valsartan up-titration are shown in Figure 2 . After 12 weeks, SBP was lower across all screening groups in both up-titration regimens, with greater reductions in those patients with higher SBP at screening. In patients with screening SBP of 100-110 mmHg, the mean ± SD reduction in SBP at 12 weeks was 1. with a more rapid up-titration. The proportions of patients with reductions of at least 20% and 30% in SBP from screening to week 12 are shown in the supplementary material online, Figure S3 and Table S4 . Larger reductions in SBP were most frequent in patients with a screening SBP of ≥140 mmHg, possibly reflecting a 'regression to the mean'. However, greater reductions in blood pressure in subjects with higher SBPs have also been seen with other antihypertensive therapies. 11 Of note, only 8.6% of patients with SBP of 100-110 mmHg at screening experienced a > 20% reduction in SBP and no patient experienced a 30% reduction from baseline.
Discussion
This post hoc analysis of the TITRATION trial has several key findings. A large majority (∼80%) of patients with low SBP levels at screening (100-110 mmHg and 111-120 mmHg) were able to tolerate the target dose of sacubitril/valsartan using a gradual up-titration regimen. In addition, regardless of SBP at screening, the majority of patients (>70%) could be up-titrated to the sacubitril/valsartan target dose without any dose interruption or down-titration. Moreover, with the gradual up-titration regimen, the mean ± SD reduction in SBP at 12 weeks was only 1.4 ± 11.2 mmHg in patients with SBP of 100-110 mmHg at screening. These observations are reassuring in view of the findings of underutilization or use of suboptimal target doses of guideline-recommended, evidence-based therapies with a hypotensive action in patients with HFrEF. 1, 12, 13 The recommendation to achieve the target doses of these agents (in patients tolerating . 14 Similar observations were reported with the use of losartan in HEAAL, 15 and there is also evidence that higher doses of carvedilol are more beneficial than lower doses. 16 However, the achievement of target doses varies widely in clinical studies. In controlled clinical trial settings, approximately 60-65% of patients tolerated the target doses of ACEIs (SOLVD), 17 ARBs (CHARM) 18, 19 and beta-blockers (MERIT-HF), 20 although it may be that in these studies some patients tolerating target doses and . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . with better outcomes had less advanced HF. In contrast, real-world observational data from the European Society of Cardiology Heart Failure Long-Term Registry show that only 29%, 24% and 18% of patients, respectively, received ACEIs, ARBs and beta-blockers at target doses. 21 In this registry, a symptomatic hypotensive episode was a major factor (in 26% of patients) contributing to non-adherence to target doses. Other factors included ongoing drug up-titration in about one-third of patients and unknown reasons in another third of patients. Concerns about possible hypotensive episodes may be another reason for avoiding further increases in treatment dose. 21 Low SBP in patients with HF (often defined as SBP of <110 − 120 mmHg) has been reported in approximately 15-25% of all HF patients and is associated with a poor prognosis. 22, 23 It may result from and reflect the severity of left ventricular systolic dysfunction (as cardiac output is a major determinant of blood pressure). In addition, low SBP may reflect the effect of HF therapies as almost all disease-modifying HF therapies have blood pressure-lowering effects. Because of fear of poor tolerance in patients with low SBP, physicians may be hesitant in optimizing HF treatment in this cohort. 22,24 -26 In a recent review, Vaduganathan et al. suggested that the clinical benefits of add-on neurohormonal blockade may be balanced or even neutralized by risk for hypotension. 26 However, reports from large HF trials, such as COPERNICUS, 27 CHARM, 28 A-HeFT 29 and Val-HeFT, 30 suggest that dosing and trial completion are limited to a greater extent by the severity of HF than by drug intolerance to HF therapy per se, as patients receiving placebo were almost as likely to discontinue as patients receiving the active study treatment, regardless of SBP. Furthermore, in line with these and more recent trial data, 28 practical guidance for the management of HF patients with low SBP emphasizes the importance of using guideline-directed therapies despite low SBP as the symptoms of hypotension may resolve as HF improves. 24 In the PARADIGM-HF study, patients were able to enter the run-in phase if their SBP was ≥100 mmHg and could be randomized if their SBP was ≥100 mmHg on sacubitril/valsartan 97 mg/103 mg twice per day. A large number of patients (n = 1747) had low SBP (<110 mmHg) at randomization. An analysis of PARADIGM-HF outcomes according to baseline and post-randomization SBP has recently been published. 31 The benefit of sacubitril/valsartan over enalapril in reducing mortality and morbidity was consistent across the range of baseline SBP values in PARADIGM-HF, although, as in TITRATION, the rates of study drug dose reduction and discontinuation were highest in patients with the lowest SBP. However, the rate of discontinuation attributable to hypotension-related AEs was similar in both treatment groups (1.3% in the sacubitril/valsartan group vs. 1% in the enalapril group).
Collectively, the present findings from TITRATION and those of PARADIGM-HF suggest that patients with SBP of ≥100 mmHg will both tolerate and benefit from sacubitril/valsartan, especially if treatment is gradually up-titrated.
Study limitations
As in the primary study, the limitations of the present analysis include the selected nature of the patients enrolled, which reflect the exclusion criteria. In addition, the study design included a 1-week, single-blind, run-in period during which the tolerability of sacubitril/valsartan 24 mg/26 mg was assessed using prespecified safety criteria (including no symptomatic hypotension and SBP of ≥95 mmHg). Furthermore, a few ACEI/ARB-naive and hospitalized patients were also included. Consequently, the present findings, and those of PARADIGM-HF, cannot be extrapolated to certain vulnerable patient groups (e.g. very elderly patients, hospitalized patients, patients in NYHA class IV, patients with a very low eGFR and those with SBP of <95 mmHg on treatment with an ACEI or ARB). Although the sacubitril/valsartan regimen allocation was double blinded by design, sacubitril/valsartan was administered as an open-label treatment in this trial. The study was conducted to accurately characterize the tolerability of the 3-and 6-week initiation/up-titration regimens, but was not powered to detect differences in AE rates between regimens and SBP categories. In addition, the SBP categories used in the present analyses were, to some extent, arbitrary. Although data were collected prospectively, the reported analyses were performed post hoc and are therefore subject to the potential biases inherent in analyses of observational data. Lastly, it is also inevitable that even if target doses are achieved, over time, some patients will be compelled to reduce the treatment dose; reassuringly, an analysis of such patients in PARADIGM-HF shows that the benefit of sacubitril/valsartan over enalapril is maintained. 
Clinical implications
In patients with HFrEF, low SBP is associated with a relatively poor prognosis and is often considered a barrier to starting and/or up-titrating HF therapies to the target dose. In this post hoc analysis of the TITRATION trial, a large majority (∼80%) of patients with low screening SBP levels (100-110 mmHg and 111-120 mmHg) were able to achieve and tolerate the target dose of sacubitril/valsartan using a gradual up-titration regimen. Reductions in SBP were also lower in patients receiving a gradual up-titration of sacubitril/valsartan. These findings suggest that a low SBP should not prevent clinicians from considering the initiation of sacubitril/valsartan, which has been definitively shown to reduce morbidity and mortality in patients with HFrEF. Figure S2 . (A) Treatment and (B) tolerability success during the post-randomization period according to systolic blood pressure at screening in patients with high/low ACEI/ARB pre-study dosing. Figure S3 . Overall proportion of patients experiencing a ≥ 20% or ≥30% decrease in systolic blood pressure from screening to week 12. Table S1 . Treatment and tolerability success during the post-randomization period for the overall study population and for up-titration regimens according to systolic blood pressure at screening. Table S2 . Treatment and tolerability success during the post-randomization period for subjects with high/low prior ACEI/ARB dosing according to systolic blood pressure at screening. Table S3 . Patients requiring dose adjustment/down-titration according to systolic blood pressure at screening. Table S4 . Proportion of patients experiencing a ≥ 20% or ≥30% decrease in systolic blood pressure from screening to week 12 according to the titration regimen.
